Remove 2025 Remove Contracts Remove Designs Remove Litigation
article thumbnail

ERA IP-focused events and courses return with 25% discount for IPKat readers

The IPKat

Accredited European Patent Litigation Certificate Course Trier & Online tutorial - Course start: 25 September 2024; Course end: 16 May 2025 ERA will offer a high-standard course giving patent attorneys the best tools to understand the legal framework and procedural rules necessary to litigate before the UPC.

article thumbnail

Guest Post: Sony fails in strike out claim against Hendrix bandmates

The IPKat

This New York action has been stayed pending resolution of the English litigation. This is an interesting legal question as the Copyright, Designs and Patents Act 1988 (the CDPA) brought in new performers’ rights, even for earlier performances such as Mitchell’s and Redding’s subject to transitional provisions regarding prior contracts.

Copyright 108
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Texas Revolution: State Legislature Creates New Business Court System to Handle Significant Commercial Disputes

LexBlog IP

Ideally, specialized business courts also promote consistent interpretations of commercial laws and contracts, thereby leading to more predictable outcomes. To that end, those with potential matters before these courts should educate themselves on the intricacies of this new avenue for Texas commercial litigation.

article thumbnail

Supporting MSME

Biswajit Sarkar Copyright Blog

As India aims for a $5 trillion economy, the MSME ministry sets ambitious goals, aiming to elevate their GDP contribution by up to 50% by 2025. This made it intricate and perplexing for litigants, especially small business owners reliant on consistent cash flow.

article thumbnail

Biosimilars 2020 Year in Review

Fish & Richardson Trademark & Copyright Thoughts

The biosimilar pathway was designed to increase competition for biologics and reduce healthcare costs. Yet 2020 saw a slowdown in biosimilar activity with the lowest number of annual biosimilar approvals since 2016 and fewer product launches than 2019—as well as a decrease in district court litigation and post-grant proceedings.